Genfit

The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for the chronic liver disease NASH in China. As part of the deal, Genfit will receive a €31M ($35M) upfront fee and up to €170M ($193M) in developmental milestone payments. The two companies will also collaborate on other development programs for […]

The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children. Genfit develops diagnostic and therapeutic tools for metabolic and inflammatory diseases, particularly those affecting the liver. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH), and the company’s plan to begin testing it in children has been supported […]

Elafibranor, Genfit’s lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and therapeutics for metabolic and inflammatory diseases. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH) – an inflammatory disease of the liver. The company has raised €180M by selling bonds […]

Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […]